Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance.
Understanding the exact role of current drugs in Covid-19 disease is essential in the era of global pandemics. Metformin which prescribed as the first-line treatment of type 2 diabetes has beneficial effects on Sars-cov2 infection. These effects are including regulation of immune system, Renin-Angiotensin System and Dipeptidyl Peptidase 4 function in Covid-19 infection. It also activates ACE2, the main receptor of Sars-cov2, in the epithelial cells of respiratory tissue through AMPK signaling and subsequently decreases the rate of viral adhesion. Metformin also declines the adherence of Sars-cov2 to DPP4 (the other receptor of the virus) on T cells. Hence, regulatory effects of metformin on membranous ACE2, and DPP4 can modulate immune reaction against Sars-cov2. Also, immunometabolic effects of metformin on inflammatory cells impair hyper-reactive immune response against the virus through reduction of glycolysis and propagation of mitochondrial oxidation. Metformin also decreases platelet aggravation and risk of thrombosis. In this article, we argue that metformin has beneficial effects on Covid-19 infection in patients with type 2 diabetes and insulin resistance. This opinion should be investigated in future clinical trials.
['Hashemi|Payam|P|', 'Pezeshki|Shaghayegh|S|https://orcid.org/0000-0002-5765-6364']
D000086382:COVID-19 D003924:Diabetes Mellitus, Type 2 D058492:Drug Repositioning D006801:Humans D007333:Insulin Resistance D008687:Metformin D000086402:SARS-CoV-2
metformin COVID-19 diabetes insulin resistance renin-angiotensin system ACE2 immunometabolism anti-inflammatory platelet aggregation